It seems like the telehealth world is constantly on the lookout for the next big thing, and right now, that buzz is all about peptides. Personally, I think it’s fascinating how a seemingly niche area of biochemistry is suddenly becoming a major talking point for companies like Hims & Hers. The recent news that the FDA is considering a review of peptides for compounding purposes has sent ripples through the market, and it’s easy to see why Hims & Hers is particularly energized by this development. What makes this particularly fascinating is the strategic pivot Hims & Hers appears to (Read more…)
Lesen Sie den vollständigen Artikel auf Papierkugel - All About Everything.